TSX Growth Companies With High Insider Ownership For July 2025

Yahoo

24-07-2025

As the Canadian stock market navigates through a landscape of delayed tariff increases and resilient economic data, investors are closely watching how these factors might influence volatility in the coming months. In such an environment, growth companies with high insider ownership can be particularly appealing, as they often signal strong confidence from those who know the business best and may offer resilience amid market fluctuations.
Top 10 Growth Companies With High Insider Ownership In Canada
Name
Insider Ownership
Earnings Growth
Tenaz Energy (TSX:TNZ)
10.4%
151.2%
SolarBank (NEOE:SUNN)
15.9%
52.1%
Robex Resources (TSXV:RBX)
24.4%
90.6%
Propel Holdings (TSX:PRL)
36.3%
31.1%
Orla Mining (TSX:OLA)
11.2%
65.7%
Enterprise Group (TSX:E)
32.2%
70.3%
Discovery Silver (TSX:DSV)
15.1%
42.6%
Burcon NutraScience (TSX:BU)
15.3%
125.9%
Aritzia (TSX:ATZ)
17.3%
27.6%
Allied Gold (TSX:AAUC)
16%
59.8%
Click here to see the full list of 46 stocks from our Fast Growing TSX Companies With High Insider Ownership screener.
Underneath we present a selection of stocks filtered out by our screen.
Knight Therapeutics
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Knight Therapeutics Inc. is engaged in acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America with a market cap of CA$608.88 million.
Operations: The company's revenue is primarily derived from its Pharmaceuticals segment, totaling CA$372.78 million.
Insider Ownership: 22.8%
Earnings Growth Forecast: 25.5% p.a.
Knight Therapeutics, a Canadian growth company with significant insider ownership, is poised for substantial earnings growth of 25.5% annually over the next three years, outpacing the broader Canadian market. Despite trading at a notable discount to its estimated fair value, Knight faces challenges with low forecasted Return on Equity and large one-off items impacting results. Recent strategic moves include acquiring exclusive rights to commercialize new products like CREXONT® in Canada and Latin America, supported by a CAD 60 million credit facility for expansion initiatives.
Click here and access our complete growth analysis report to understand the dynamics of Knight Therapeutics.
In light of our recent valuation report, it seems possible that Knight Therapeutics is trading behind its estimated value.
Kits Eyecare
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Kits Eyecare Ltd. operates a digital eyecare platform in the United States and Canada, with a market cap of CA$510.19 million.
Operations: The company's revenue from the sale of eyewear products amounts to CA$171.15 million.
Insider Ownership: 22.6%
Earnings Growth Forecast: 54.5% p.a.
Kits Eyecare demonstrates robust growth potential, with earnings projected to rise significantly at 54.5% annually over the next three years, surpassing Canadian market averages. The company recently became profitable and trades 60.3% below its estimated fair value, indicating potential upside. Insider activity is positive with substantial buying in the past quarter. Kits announced a share buyback program for up to 1,600,300 shares to enhance shareholder value and reported strong Q1 results with CAD 46.6 million in sales and CAD 1.6 million net income.
Delve into the full analysis future growth report here for a deeper understanding of Kits Eyecare.
Insights from our recent valuation report point to the potential undervaluation of Kits Eyecare shares in the market.
WELL Health Technologies
Simply Wall St Growth Rating: ★★★★☆☆
Overview: WELL Health Technologies Corp. is a practitioner-focused digital healthcare company operating in Canada, the United States, and internationally, with a market cap of CA$1.19 billion.
Operations: The company's revenue segments include SaaS and Technology Services (CA$79.59 million), Specialized-provider Staffing (CA$145.96 million), Canadian Patient Services - Primary (CA$207.89 million), WELL Health USA Patient Services - Primary WISP (CA$109.39 million), Canadian Patient Services - Specialized Myhealth (CA$135.67 million), WELL Health USA Patient Services - Primary Circle Medical (CA$85.37 million), and WELL Health USA Patient Services - Specialized CRH Medical (CA$235.22 million).
Insider Ownership: 22.6%
Earnings Growth Forecast: 95% p.a.
WELL Health Technologies is poised for growth, with earnings expected to rise 95.03% annually, outpacing Canadian market averages. The company trades at 63.3% below its estimated fair value, suggesting potential upside. Recent strategic moves include expanding primary care capacity and securing a $200 million credit facility to support growth initiatives. Despite a Q1 net loss of C$46.57 million, WELL's focus on digital health solutions and physician recruitment underscores its commitment to addressing Canada's healthcare access challenges effectively.
Navigate through the intricacies of WELL Health Technologies with our comprehensive analyst estimates report here.
The valuation report we've compiled suggests that WELL Health Technologies' current price could be quite moderate.
Turning Ideas Into Actions
Navigate through the entire inventory of 46 Fast Growing TSX Companies With High Insider Ownership here.
Want To Explore Some Alternatives? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include TSX:GUD TSX:KITS and TSX:WELL.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email [e-mail]